Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EBOS Group Limited ( (AU:EBO) ) has provided an update.
EBOS Group Limited announced the status of performance rights for the period from July 2022 to June 2025, revealing that 296,674 rights have lapsed due to unmet conditions, while 19,994 rights have vested resulting in the issuance of ordinary shares, and 352 rights have been settled with a cash payment. This update reflects the company’s ongoing management of its performance rights, which could impact its financial structure and stakeholder interests.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$34.82 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited operates in the healthcare and animal care sectors, providing a range of products and services. The company is focused on serving markets in New Zealand and Australia, with a strong presence in the distribution of healthcare, medical, and pharmaceutical products.
Average Trading Volume: 105,511
Technical Sentiment Signal: Sell
Current Market Cap: A$6.08B
Find detailed analytics on EBO stock on TipRanks’ Stock Analysis page.